search
Back to results

To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee

Primary Purpose

Osteoarthritis

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Canakinumab
Placebo to canakinumab
Naproxen
Placebo to Naproxen
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis focused on measuring Osteo arthritis, pain control, intra- articular injections, Knee OA

Eligibility Criteria

40 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Written informed consent must be obtained before any assessment is performed.
  2. Male and female patients aged 40 - 80 years (inclusive).
  3. Diagnosis of knee osteoarthritis
  4. Radiographic evidence of tibiofemoral compartment osteoarthritis
  5. Pain in the knee during the last 24 hours.The patients should also have had pain in the affected knee on most days over the last month.
  6. Patients who are willing to discontinue all non-steroidal anti-inflammatory drugs (NSAIDs) or other analgesic medication taken for any condition, including their knee pain,
  7. Patients who are on stable dose of opioids for at least 1 month before screening can continue to take their opioid at this stable dose throughout the study.
  8. Patients must also be willing to abstain from any intra-articular or peri-articular injections to the knee or surgery during the treatment period
  9. Patients who, if they are currently taking aspirin (325 mg/day or less; as anti-coagulants), are willing to remain on a stable dose one month prior to screening and throughout the study

Exclusion Criteria:

  1. Subjects with known hypersensitivity to any biological or investigational drugs.
  2. Patients with contraindications to knee injections
  3. Patients with joint effusion
  4. Patients should not have rheumatoid arthritis or any connective tissue like disease
  5. Secondary osteoarthritis with history and/or any evidence of the following diseases: septic arthritis, inflammatory joint disease, gout, Paget's disease of the bone, articular fracture, major dysplasias or congenital abnormality, ochronosis, acromegaly, hemochromatosis, Wilson's disease, primary osteochondromatosis, juvenile chronic arthritis with continued activity in adulthood, heritable disorders (e.g. hypermobility). Patients with secondary osteoarthritis following menisectomy or injuries of a collateral or cruciate ligament are not excluded.
  6. Presence or history of underlying metabolic, endocrine, hematologic, pulmonary, cardiac, blood, renal, hepatic, infectious, psychiatric or gastrointestinal conditions
  7. Evidence of tuberculosis (TB)
  8. One of the risk factors for TB such as:

    1. Substance abuse (e.g. injection or non-injection)
    2. Health-care workers with unprotected exposure to patients who are at high risk of TB
    3. Patients with TB disease before the identification and correct airborne precautions of the patient
    4. close contact (i.e. share the same air space in a household or other enclosed environment for a prolonged period (days or weeks, not minutes or hours)) with a person with active pulmonary TB disease.
  9. Significant medical problems, including but not limited to the following: uncontrolled hypertension,congestive heart failure, uncontrolled diabetes type I and II
  10. Subjects with evidence of hepatic or blood coagulation disorders (i.e. hemophilia, etc), anemia, idiopathic thrombocytopenic purpura, or gastrointestinal disorder: severe hepatic disease, history of alcohol and drug abuse; disease of gall bladder and pancreas; active peptic ulceration, gastrointestinal bleeding or history of severe gastro-esophageal reflux disease or severe hiatus hernia; inflammatory bowel disease.
  11. Use of any therapeutic protein drug (e.g. anti-tumor necrosis factor alpha (TNFα) antibody)
  12. Presence of severe renal function impairment. History of renal trauma, glomerulonephritis, patients with one kidney, or renal failure requiring regular dialysis treatment.
  13. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive pregnancy test (serum or urine).
  14. Subjects with known contra-indications to naproxen (e.g. heart or circulation problems, history of ulcer disease etc.), analgesics, antipyretics, or NSAIDs.
  15. Disease of the spine or other lower extremity joints which may interfere with the assessment of the target joint.
  16. Surgery on the knee within the last year. Observational arthroscopy, arthroscopic surgery or lavage of the knee within the last 6 months.
  17. Use of assistive devices other than a cane (walking stick) or knee brace.
  18. Subjects who have experienced, any time in the past, asthma, acute rhinitis, nasal polyps, angioneurotic edema, urticaria or other allergic-type reaction after taking acetylsalicylic acid (ASA)/ aspirin or NSAIDs.
  19. Any history of prior peptic ulcer disease or prior NSAID gastrointestinal complications for the past 5 years.

Other protocol defined inclusion/exclusion criteria may apply.

Sites / Locations

  • Pinnacle Research Group, LLC
  • Arizona Arthritis & Rheumatology Research, PLLC
  • San Diego Arthritis & Osteoporosis Medical Clinic
  • Westlake Medical Research
  • Rush-Presbyterian St. Lukes Medical Center
  • Cotton O'Neil Clinical Research Institute
  • Altoona Center for Clinical Research
  • Volunteer Research Group
  • Novartis Investigative site
  • Novartis Investigative site
  • Novartis Investigative site
  • Novartis Investigative site
  • Novartis Investigative site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Active Comparator

Arm Label

Part A: Canakinumab

Part A: Placebo

Part B: Canakinumab

Part B: Placebo

Part B: Naproxen

Arm Description

In this ascending dose part, participants received a single intra-articular injection of canakinumab. The beginning dose was 150 mg, escalating to the 300 mg dose and then to 600 mg.

Participants received a single intra-articular injection of canakinumab-matching placebo.

Participants received a single intra-articular injection of canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.

Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.

Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.

Outcomes

Primary Outcome Measures

Part A: Number of Participants With Intolerance Events
An intolerance event is defined as an acute inflammatory reaction, characterized by a 30 mm increase in pain (on a 100 mm visual analog scale (VAS) and associated with a new or worsened synovial fluid effusion within 3 days following the intra-articular (i.a.) injection. If baseline VAS pain score is ≥ 70 mm, an intolerance event is defined as an increase in pain by 20 mm on a 100 mm VAS associated with new or worsened synovial fluid effusion within 3 days following the i.a. injection. If baseline VAS pain score is ≥ 80 mm, an intolerance event is defined as an increase in pain by 10 mm on a 100 mm VAS associated with new or worsened synovial fluid effusion within 3 days following the i.a. injection. If baseline pain score is ≥ 90 mm, an intolerance event is defined as the patients experiencing an unspecified increase in pain on a 100 mm VAS associated with new or worsened synovial fluid effusion within 3 days following the i.a. injection.
Part B: Change From Baseline to Day 4 in Pain Using 100 mm Visual Analog Scale (VAS)
After walking for 20 meters, participants were asked to assess the pain in their affected knee on a 100 mm linear visual analog scale ranging from no pain (0 mm) to unbearable pain (100 mm). A negative change from Baseline score indicates improvement. Results are from a Bayesian analysis of covariance (ANCOVA) model, fitting baseline pain VAS score as a covariate, time by treatment as fixed effects, region and subject as random effects.
Part B: Change From Baseline to Week 4 in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale
The Western Ontario and McMaster osteoarthritis Index (WOMAC) pain subscale asks patients to rate pain in the index knee joint in the last 48 hours doing different activities on a scale from none (0) to extreme pain (4). The answers are summed and the total pain subscale score ranges from 0 to 20, where higher scores indicate more pain. A negative change from Baseline score indicates improvement. Results are from a Bayesian ANCOVA model, fitting baseline WOMAC pain score as a covariate, time by treatment as fixed effects, region and patient as random effects.

Secondary Outcome Measures

Part B: Change From Baseline in Pain Using 100 mm Visual Analog Scale (VAS)
After walking for 20 meters, participants were asked to assess the pain in their affected knee on a 100 mm linear visual analog scale ranging from no pain (0 mm) to unbearable pain (100 mm). Results are from a Bayesian ANCOVA model, fitting baseline pain VAS score as a covariate, time by treatment as fixed effects, region and patient as random effects.
Part B: Percentage of Responders in the Pain 100 mm Visual Analog Scale (VAS)
A responder is defined as a participant with a 50% or greater reduction from baseline on the VAS scale for pain assessment. After walking for 20 meters, participants were asked to assess the pain in their affected knee on a 100 mm linear visual analog scale ranging from no pain (0 mm) to unbearable pain (100 mm).
Part B: Change From Baseline in WOMAC Pain, Stiffness and Physical Function Subscales
The WOMAC consists of 3 subscales: The Pain subscale asks patients to rate pain in the index knee joint in the last 48 hours during walking, using stairs, in bed, sitting or lying, and standing on a scale from none (0) to extreme pain (4). The answers are summed and the total pain subscale score ranges from 0-20. The Stiffness subscale assesses stiffness in the index knee joint during the last 48 hours doing different activities on a scale from none (0) to extreme stiffness (4). The total stiffness subscale score ranges from 0-8. The Physical Function subscale assesses difficulty performing daily physical activities during the last 48 hours on a scale from none (0) to extreme difficulty (4). The total physical function subscale score ranges from 0-68. Higher scores indicate more pain/stiffness/difficulty. Results are from a Bayesian ANCOVA model, with baseline WOMAC score as a covariate, time by treatment as fixed effects, region and patient as random effects.
Part B: Proportion of Participants Who Used Rescue Analgesic During Study
Participants were permitted to take oral rescue medication (Acetaminophen ≤ 4 gram/day) up until 24 hours of a scheduled assessment visit during the 12-week treatment period. The estimates shown are the Kaplan-Meier estimates of the proportion of participants that took rescue medication.
Patient's Global Assessment of Response to Treatment on Day 4
Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Patient's Global Assessment of Response to Treatment at Week 2
Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Patient's Global Assessment of Response to Treatment at Week 4
Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Patient's Global Assessment of Response to Treatment at Week 8
Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Patient's Global Assessment of Response to Treatment at Week 12
Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Part B: Physician's Global Assessment of Response to Treatment at Day 4
The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Part B: Physician's Global Assessment of Response to Treatment at Week 2
The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Part B: Physician's Global Assessment of Response to Treatment at Week 4
The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Part B: Physician's Global Assessment of Response to Treatment at Week 8
The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Part B: Physician's Global Assessment of Response to Treatment at Week 12
The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Maximum Observed Plasma Concentration of Canakinumab (Cmax)
Time to Reach the Maximum Observed Plasma Concentration of Canakinumab (Tmax)
Area Under the Concentration Time Curve up to the Last Measurable Concentration (AUClast)
Area Under the Concentration Time Curve From Time Zero to Infinity AUC(0-inf)
Terminal Phase Half-life (t1/2) of Canakinumab
The time it takes for the concentration level of canakinumab to fall to 50% of the original value.
Apparent Clearance of Canakinumab From Plasma (CL/F)
Apparent Volume of Distribution During Terminal Phase (Vz/F)

Full Information

First Posted
July 9, 2010
Last Updated
September 28, 2012
Sponsor
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01160822
Brief Title
To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee
Official Title
A Randomized, Double Blind, Placebo and Naproxen Controlled, Multi-center, Study to Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee
Study Type
Interventional

2. Study Status

Record Verification Date
September 2012
Overall Recruitment Status
Completed
Study Start Date
April 2010 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
July 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals

4. Oversight

5. Study Description

Brief Summary
The purpose of this study was to determine whether, in patients with mild to moderate knee osteoarthritis, canakinumab is safe and tolerable when injected intra-articularly.
Detailed Description
This is a randomized, double-blind, parallel group, placebo controlled 18 weeks study, consisting of two parts: Part A: an ascending single dose part in which the safety and tolerability of up to 4 different canakinumab doses are studied (starting dose 150 mg, maximum dose 600 mg). Part B: a double-dummy, active-controlled, parallel design part in which the pain reduction of the canakinumab dose selected from part A is studied in comparison to Placebo and Naproxen.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
Keywords
Osteo arthritis, pain control, intra- articular injections, Knee OA

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
169 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Part A: Canakinumab
Arm Type
Experimental
Arm Description
In this ascending dose part, participants received a single intra-articular injection of canakinumab. The beginning dose was 150 mg, escalating to the 300 mg dose and then to 600 mg.
Arm Title
Part A: Placebo
Arm Type
Placebo Comparator
Arm Description
Participants received a single intra-articular injection of canakinumab-matching placebo.
Arm Title
Part B: Canakinumab
Arm Type
Experimental
Arm Description
Participants received a single intra-articular injection of canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.
Arm Title
Part B: Placebo
Arm Type
Placebo Comparator
Arm Description
Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.
Arm Title
Part B: Naproxen
Arm Type
Active Comparator
Arm Description
Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.
Intervention Type
Biological
Intervention Name(s)
Canakinumab
Other Intervention Name(s)
ACZ885
Intervention Description
Intra-articular injection
Intervention Type
Drug
Intervention Name(s)
Placebo to canakinumab
Intervention Description
Intra-articular injection
Intervention Type
Drug
Intervention Name(s)
Naproxen
Intervention Description
Tablets for oral administration
Intervention Type
Drug
Intervention Name(s)
Placebo to Naproxen
Intervention Description
Tablets for oral administration
Primary Outcome Measure Information:
Title
Part A: Number of Participants With Intolerance Events
Description
An intolerance event is defined as an acute inflammatory reaction, characterized by a 30 mm increase in pain (on a 100 mm visual analog scale (VAS) and associated with a new or worsened synovial fluid effusion within 3 days following the intra-articular (i.a.) injection. If baseline VAS pain score is ≥ 70 mm, an intolerance event is defined as an increase in pain by 20 mm on a 100 mm VAS associated with new or worsened synovial fluid effusion within 3 days following the i.a. injection. If baseline VAS pain score is ≥ 80 mm, an intolerance event is defined as an increase in pain by 10 mm on a 100 mm VAS associated with new or worsened synovial fluid effusion within 3 days following the i.a. injection. If baseline pain score is ≥ 90 mm, an intolerance event is defined as the patients experiencing an unspecified increase in pain on a 100 mm VAS associated with new or worsened synovial fluid effusion within 3 days following the i.a. injection.
Time Frame
Baseline to Day 3
Title
Part B: Change From Baseline to Day 4 in Pain Using 100 mm Visual Analog Scale (VAS)
Description
After walking for 20 meters, participants were asked to assess the pain in their affected knee on a 100 mm linear visual analog scale ranging from no pain (0 mm) to unbearable pain (100 mm). A negative change from Baseline score indicates improvement. Results are from a Bayesian analysis of covariance (ANCOVA) model, fitting baseline pain VAS score as a covariate, time by treatment as fixed effects, region and subject as random effects.
Time Frame
Baseline and Day 4
Title
Part B: Change From Baseline to Week 4 in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale
Description
The Western Ontario and McMaster osteoarthritis Index (WOMAC) pain subscale asks patients to rate pain in the index knee joint in the last 48 hours doing different activities on a scale from none (0) to extreme pain (4). The answers are summed and the total pain subscale score ranges from 0 to 20, where higher scores indicate more pain. A negative change from Baseline score indicates improvement. Results are from a Bayesian ANCOVA model, fitting baseline WOMAC pain score as a covariate, time by treatment as fixed effects, region and patient as random effects.
Time Frame
Baseline and Week 4
Secondary Outcome Measure Information:
Title
Part B: Change From Baseline in Pain Using 100 mm Visual Analog Scale (VAS)
Description
After walking for 20 meters, participants were asked to assess the pain in their affected knee on a 100 mm linear visual analog scale ranging from no pain (0 mm) to unbearable pain (100 mm). Results are from a Bayesian ANCOVA model, fitting baseline pain VAS score as a covariate, time by treatment as fixed effects, region and patient as random effects.
Time Frame
Baseline and Weeks 4, 8 and 12
Title
Part B: Percentage of Responders in the Pain 100 mm Visual Analog Scale (VAS)
Description
A responder is defined as a participant with a 50% or greater reduction from baseline on the VAS scale for pain assessment. After walking for 20 meters, participants were asked to assess the pain in their affected knee on a 100 mm linear visual analog scale ranging from no pain (0 mm) to unbearable pain (100 mm).
Time Frame
Baseline, Day 4, Weeks 1, 2, 4, 8 and 12
Title
Part B: Change From Baseline in WOMAC Pain, Stiffness and Physical Function Subscales
Description
The WOMAC consists of 3 subscales: The Pain subscale asks patients to rate pain in the index knee joint in the last 48 hours during walking, using stairs, in bed, sitting or lying, and standing on a scale from none (0) to extreme pain (4). The answers are summed and the total pain subscale score ranges from 0-20. The Stiffness subscale assesses stiffness in the index knee joint during the last 48 hours doing different activities on a scale from none (0) to extreme stiffness (4). The total stiffness subscale score ranges from 0-8. The Physical Function subscale assesses difficulty performing daily physical activities during the last 48 hours on a scale from none (0) to extreme difficulty (4). The total physical function subscale score ranges from 0-68. Higher scores indicate more pain/stiffness/difficulty. Results are from a Bayesian ANCOVA model, with baseline WOMAC score as a covariate, time by treatment as fixed effects, region and patient as random effects.
Time Frame
Baseline and Weeks 4, 8 and 12
Title
Part B: Proportion of Participants Who Used Rescue Analgesic During Study
Description
Participants were permitted to take oral rescue medication (Acetaminophen ≤ 4 gram/day) up until 24 hours of a scheduled assessment visit during the 12-week treatment period. The estimates shown are the Kaplan-Meier estimates of the proportion of participants that took rescue medication.
Time Frame
Day 4, Weeks 1, 2, 4, 8 and 12
Title
Patient's Global Assessment of Response to Treatment on Day 4
Description
Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Time Frame
Day 4
Title
Patient's Global Assessment of Response to Treatment at Week 2
Description
Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Time Frame
Week 2
Title
Patient's Global Assessment of Response to Treatment at Week 4
Description
Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Time Frame
Week 4
Title
Patient's Global Assessment of Response to Treatment at Week 8
Description
Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Time Frame
Week 8
Title
Patient's Global Assessment of Response to Treatment at Week 12
Description
Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Time Frame
Week 12
Title
Part B: Physician's Global Assessment of Response to Treatment at Day 4
Description
The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Time Frame
Day 4
Title
Part B: Physician's Global Assessment of Response to Treatment at Week 2
Description
The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Time Frame
Week 2
Title
Part B: Physician's Global Assessment of Response to Treatment at Week 4
Description
The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Time Frame
Week 4
Title
Part B: Physician's Global Assessment of Response to Treatment at Week 8
Description
The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Time Frame
Week 8
Title
Part B: Physician's Global Assessment of Response to Treatment at Week 12
Description
The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.
Time Frame
Week 12
Title
Maximum Observed Plasma Concentration of Canakinumab (Cmax)
Time Frame
Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.
Title
Time to Reach the Maximum Observed Plasma Concentration of Canakinumab (Tmax)
Time Frame
Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.
Title
Area Under the Concentration Time Curve up to the Last Measurable Concentration (AUClast)
Time Frame
Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.
Title
Area Under the Concentration Time Curve From Time Zero to Infinity AUC(0-inf)
Time Frame
Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.
Title
Terminal Phase Half-life (t1/2) of Canakinumab
Description
The time it takes for the concentration level of canakinumab to fall to 50% of the original value.
Time Frame
Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.
Title
Apparent Clearance of Canakinumab From Plasma (CL/F)
Time Frame
Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.
Title
Apparent Volume of Distribution During Terminal Phase (Vz/F)
Time Frame
Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Written informed consent must be obtained before any assessment is performed. Male and female patients aged 40 - 80 years (inclusive). Diagnosis of knee osteoarthritis Radiographic evidence of tibiofemoral compartment osteoarthritis Pain in the knee during the last 24 hours.The patients should also have had pain in the affected knee on most days over the last month. Patients who are willing to discontinue all non-steroidal anti-inflammatory drugs (NSAIDs) or other analgesic medication taken for any condition, including their knee pain, Patients who are on stable dose of opioids for at least 1 month before screening can continue to take their opioid at this stable dose throughout the study. Patients must also be willing to abstain from any intra-articular or peri-articular injections to the knee or surgery during the treatment period Patients who, if they are currently taking aspirin (325 mg/day or less; as anti-coagulants), are willing to remain on a stable dose one month prior to screening and throughout the study Exclusion Criteria: Subjects with known hypersensitivity to any biological or investigational drugs. Patients with contraindications to knee injections Patients with joint effusion Patients should not have rheumatoid arthritis or any connective tissue like disease Secondary osteoarthritis with history and/or any evidence of the following diseases: septic arthritis, inflammatory joint disease, gout, Paget's disease of the bone, articular fracture, major dysplasias or congenital abnormality, ochronosis, acromegaly, hemochromatosis, Wilson's disease, primary osteochondromatosis, juvenile chronic arthritis with continued activity in adulthood, heritable disorders (e.g. hypermobility). Patients with secondary osteoarthritis following menisectomy or injuries of a collateral or cruciate ligament are not excluded. Presence or history of underlying metabolic, endocrine, hematologic, pulmonary, cardiac, blood, renal, hepatic, infectious, psychiatric or gastrointestinal conditions Evidence of tuberculosis (TB) One of the risk factors for TB such as: Substance abuse (e.g. injection or non-injection) Health-care workers with unprotected exposure to patients who are at high risk of TB Patients with TB disease before the identification and correct airborne precautions of the patient close contact (i.e. share the same air space in a household or other enclosed environment for a prolonged period (days or weeks, not minutes or hours)) with a person with active pulmonary TB disease. Significant medical problems, including but not limited to the following: uncontrolled hypertension,congestive heart failure, uncontrolled diabetes type I and II Subjects with evidence of hepatic or blood coagulation disorders (i.e. hemophilia, etc), anemia, idiopathic thrombocytopenic purpura, or gastrointestinal disorder: severe hepatic disease, history of alcohol and drug abuse; disease of gall bladder and pancreas; active peptic ulceration, gastrointestinal bleeding or history of severe gastro-esophageal reflux disease or severe hiatus hernia; inflammatory bowel disease. Use of any therapeutic protein drug (e.g. anti-tumor necrosis factor alpha (TNFα) antibody) Presence of severe renal function impairment. History of renal trauma, glomerulonephritis, patients with one kidney, or renal failure requiring regular dialysis treatment. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive pregnancy test (serum or urine). Subjects with known contra-indications to naproxen (e.g. heart or circulation problems, history of ulcer disease etc.), analgesics, antipyretics, or NSAIDs. Disease of the spine or other lower extremity joints which may interfere with the assessment of the target joint. Surgery on the knee within the last year. Observational arthroscopy, arthroscopic surgery or lavage of the knee within the last 6 months. Use of assistive devices other than a cane (walking stick) or knee brace. Subjects who have experienced, any time in the past, asthma, acute rhinitis, nasal polyps, angioneurotic edema, urticaria or other allergic-type reaction after taking acetylsalicylic acid (ASA)/ aspirin or NSAIDs. Any history of prior peptic ulcer disease or prior NSAID gastrointestinal complications for the past 5 years. Other protocol defined inclusion/exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Pinnacle Research Group, LLC
City
Anniston
State/Province
Alabama
ZIP/Postal Code
36207
Country
United States
Facility Name
Arizona Arthritis & Rheumatology Research, PLLC
City
Mesa
State/Province
Arizona
ZIP/Postal Code
85202
Country
United States
Facility Name
San Diego Arthritis & Osteoporosis Medical Clinic
City
San Diego
State/Province
California
ZIP/Postal Code
92108
Country
United States
Facility Name
Westlake Medical Research
City
Westlake Village
State/Province
California
ZIP/Postal Code
91361
Country
United States
Facility Name
Rush-Presbyterian St. Lukes Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
Cotton O'Neil Clinical Research Institute
City
Topeka
State/Province
Kansas
ZIP/Postal Code
66606
Country
United States
Facility Name
Altoona Center for Clinical Research
City
Duncansville
State/Province
Pennsylvania
ZIP/Postal Code
16635
Country
United States
Facility Name
Volunteer Research Group
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37920
Country
United States
Facility Name
Novartis Investigative site
City
Helsinki
Country
Finland
Facility Name
Novartis Investigative site
City
Kuopio
Country
Finland
Facility Name
Novartis Investigative site
City
Creteil
Country
France
Facility Name
Novartis Investigative site
City
Berlin
Country
Germany
Facility Name
Novartis Investigative site
City
Erlangen
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee

We'll reach out to this number within 24 hrs